AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
91.52
+0.52 (0.57%)
At close: Nov 24, 2025, 4:00 PM EST
91.41
-0.11 (-0.12%)
After-hours: Nov 24, 2025, 7:23 PM EST
AstraZeneca Employees
AstraZeneca had 92,900 employees as of December 31, 2024. The number of employees increased by 3,000 or 3.34% compared to the previous year.
Employees
92,900
Change (1Y)
3,000
Growth (1Y)
3.34%
Revenue / Employee
$625,694
Profits / Employee
$101,173
Market Cap
283.06B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
| Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
| Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
| Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
| Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
| Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
| Dec 31, 2013 | 51,500 | -200 | -0.39% |
| Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
| Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
| Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
| Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
| Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
| Dec 31, 2007 | 67,400 | 600 | 0.90% |
| Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
| Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
| Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
| Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
| Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AZN News
- 8 hours ago - AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows - Benzinga
- 1 day ago - Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology - PRNewsWire
- 3 days ago - AstraZeneca to invest $2 billion as part of US manufacturing push - Reuters
- 3 days ago - AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth - Business Wire
- 6 days ago - Why biotech and drug stocks are on the mend even though the rest of the market is hurting - Market Watch
- 6 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 10 days ago - Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes - Reuters
- 13 days ago - FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines - Reuters